HIV infection 25 mg PO q24h

If co-administrated with Rifabutin, 50 mg PO q24h


Safety and efficacy in pediatric patients have not been established

Mild or moderate hepatic impairment No dose adjustment

Severe hepatic impairment No data

Mild or moderate renal adjustment No dose adjustment

Severe renal impairment, ESRD Use with caution

General Information

Treatment of HIV infection.

Monitor viral load prior to initiation or modification of treatment.

Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.

Monitor hepatitis B screening at baseline and with modification of ARV treatment.

Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.

Monitor ALT,AST, and total bilirubin at baseline and with modification of treatment.


  • Rash

  • Raised cholesterol

  • Increased liver enzymes

  • Headache

  • Insomnia


  • Hypersensitivity reaction

  • Hepatotoxicity

  • Psychiatric effects

  • Membranous glomerulonephritis

  • Mesangial proliferative glomerulonephritis

  • CYP3A4 substrates

  • Proton pump inhibitors

  • QT prolonging drugs

  • Carbamazepine

  • Phenobarbital

  • Phenytoin

  • Rifampin

  • Oxcarbazepine

  • Dexamethasone

  • Rifapentine

  • Saquinavir

  • St. John’s Wort

Antimicrobial class: Antiretroviral, Non-nucleoside reverse transcriptase inhibitor

Pregnancy category: B

Average serum half life: 50 hours

Precautions: QT interval prolongation has been reported; use with caution with coadministration of other medications associated with an increased risk of torsade de pointes.

Monitoring recommended with underlying hepatic disease or marked elevations in baseline transaminases; consider monitoring in patients without preexisting hepatic impairment or other risk factors.

Discontinue immediately if signs or symptoms of severe skin and hypersensitivity reactions develop.

Depressive disorders have been reported; evaluate benefit and risk of continued treatment.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.